BioMarin Pharmaceutical Inc.

BMRN | NASDAQ

Price Alert Chart Builder DCF Calculator

$64.44

+$0.38 (+0.59%)

Sep 22, 2026, 1:14 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.59%

(1D)

Rating

Updated: Aug 27, 2026

45.1

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $12.46B

1D Range

63.37 64.79

52W Range

49.26 70.98

Valuation (TTM)

PE 164.26

PB 1.96

EV/EBITDA 136.44

Valuation (NTM)

Forward PE 9.50

Forward PEG 5.18

Price Target $90.88

Cash Flow

FCF Yield 7.6%

SBC Adj. FCF Yield 5.5%

SBC Impact -27.6%

Margins

Gross Margin 75.5%

Operating Margin 8.0%

FCF Margin 27.5%

Growth (CAGR)

Revenue 3Y | 5Y 15.1% | 12.2%

Dil EPS 3Y | 5Y -8.6% | -38.1%

FCF 3Y | 5Y 184.1% | 40.6%

Returns

ROA 0.6%

ROE 1.2%

ROIC 1.3%

Financial Health

Net Debt

$3.31B

Current Ratio 2.39

Interest Coverage 3.27

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The c...

Sector Healthcare

Industry Biotechnology

Employees 3,221

IPO Date Jul 25, 1999

Website www.biomarin.com

Fiscal Year January - December

Full Company Profile

Latest News

1 day ago · seekingalpha.com

BioMarin: Why I See Significant Upside Into 2027

Q4 2026/ 2027 will be rich in catalysts for BioMarin Pharmaceutical Inc. From the presentation of 12 mg/kg BMN 351 Phase 1/2 data in Duchenne muscular dystrophy by year-end 2026 to a potential H1 2027 approval of Voxzogo for hypochondroplasia. BioMarin raised its full-year 2026 revenue guidance from $3.83 billion-$3.93 billion to $3.88 billion-$3.93 billion.

4 days ago · marketbeat.com

BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone

BioMarin Pharmaceutical NASDAQ: BMRN said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth plans for newly acquired rare-disease products, VOXZOGO and several pipeline programs at Morgan Stanley's Global Healthcare Conference.

6 days ago · zacks.com

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

8 days ago · seekingalpha.com

BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

8 days ago · prnewswire.com

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D.

12 days ago · seekingalpha.com

BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

12 days ago · seekingalpha.com

BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

13 days ago · seekingalpha.com

BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

13 days ago · prnewswire.com

BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence

Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting VOXZOGO demonstrated statistically significant improvements across multiple measures of growth, including annualized growth velocity, standing height, height Z-score and arm span BioMarin recently submitted a supplemental New Drug Application (sNDA) to the FDA to support expanding treatment with VOXZOGO to include children with hypochondroplasia SAN RAFAEL, Calif., Sept. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO® (vosoritide) in children with hypochondroplasia were published in New England Journal of Medicine (NEJM) Evidence and presented at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting.